Investors Urged to Participate in PROCEPT BioRobotics Class Action Amid Major Losses

Robbins LLP, a law firm specializing in shareholder rights, is actively encouraging investors in PROCEPT BioRobotics Corporation (NASDAQ: PRCT) to step forward and participate in a recently filed securities class action. This legal action is particularly significant as it aims to protect the rights of investors who purchased common stock in PROCEPT BioRobotics between February 28, 2024, and February 25, 2026—a period marked by considerable financial turbulence for the company.

Class Action Overview

The core of the class action revolves around allegations that PROCEPT made materially misleading statements regarding its business operations and financial health, which ultimately led to a considerable decline in stock value. Investors who endured substantial financial losses during the specified class period are encouraged to evaluate their legal rights, as the lawsuit seeks to provide them with appropriate recourse.

Key Allegations

The complaint against PROCEPT suggests a range of serious misrepresentations:
1. The company purportedly employed an extensive discount program designed to entice larger bulk orders.
2. An undisclosed discount initiative artificially inflated the reported sales and revenue figures, misrepresenting the company's actual performance.
3. Throughout the class period, PROCEPT's customer orders for handpiece units reportedly exceeded the actual demand, leading to significant overstock situations.
4. By the end of this period, it was revealed that more than 10,000 excess handpiece units had accumulated within PROCEPT's customer base, indicating a misalignment between sales and actual procedures being performed.

Moreover, the lawsuit highlights that PROCEPT had consistently overstated its handpiece unit sales and also faced undisclosed operational risks that significantly jeopardized its financial standing. Notably, the company failed to achieve its projected sales and revenue figures for 2025, which lacked a realistic basis.

What Led to the Stock Decline?

The stock's decline was not sudden but rather a series of cumulative announcements that revealed PROCEPT's mismanagement. After disclosing second-quarter earnings on August 6, 2025, the company reported that handpiece shipments had unexpectedly dropped, subsequently reducing the consensus sales forecasts. The third-quarter earnings report issued on November 4, 2025, confirmed an even more disappointing outlook, leading to further re-evaluations of sales targets.

Then, in February 2026, PROCEPT's disclosure of actual procedures performed over the last three years exposed even more dire revelations. The substantial existence of excess inventory was alarming to stakeholders, resulting in a sharp decline of more than 18% in stock price over just two days. Following these disclosures, the stock's value continued to fall, leading to a price drop below $18 per share by July 2026.

Eligibility and Deadlines

Investors who suffered losses within the specified class action period may have legal entitlements under federal securities laws. The firm is seeking lead plaintiffs, which are court-appointed investors who represent the broader interests of all class members during the litigation process. Importantly, individuals can still participate in any recovery without being a lead plaintiff.

Potential participants should be aware that the deadline to seek appointment as lead plaintiff is set for September 22, 2026. Robbins LLP offers representation on a contingency fee basis, meaning that investors do not have to incur any upfront costs.

How to Get Involved

For more information about the PROCEPT BioRobotics Corporation class action and to see if you qualify to participate, please reach out to Robbins LLP. They welcome inquiries via email or phone, and the process is straightforward and designed to support investors seeking restitution for their losses.

Robbins LLP has a proven track record of effectively representing investors in securities fraud cases, having recovered more than $1 billion for clients and implemented significant corporate governance reforms. The attorneys at Robbins LLP emphasize that companies must provide accurate and complete information to maintain fairness and efficiency within the market.

For investors interested in staying updated on this class action or to receive alerts about potential settlements, signing up for notifications from Robbins LLP is advisable.

This announcement serves as a crucial opportunity for affected investors to reclaim losses stemming from misleading representations made by PROCEPT BioRobotics Corporation during a tumultuous time. Don't miss the chance to engage in your right as a shareholder.